𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer

✍ Scribed by Rinaa S. Punglia; Jennifer Cullen; David G. McLeod; Yongmei Chen; Anthony V. D'Amico


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
80 KB
Volume
110
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND.

An increasing prostate‐specific antigen (PSA) velocity is associated with a shorter survival after local therapy for prostate cancer. In this study, the authors evaluated whether PSA velocity was associated with prostate cancer detection and grade at diagnosis after adjusting for established predictors.

METHODS.

Between January 1989 and December 2003, 914 men who had PSA levels β‰₯4 ng/mL were identified by using the Center for Prostate Disease Research (CPDR) multicenter national database, including 541 men who were diagnosed with prostate cancer. Multivariable logistic regression analyses were performed that included continuous variables (PSA velocity and level, number of prior negative biopsies, and age) along with categorical variables (ethnicity and family history) were used to identify the factors associated with prostate cancer detection and grade.

RESULTS.

An increasing PSA velocity was associated with Gleason scores from 7 to 10 versus Gleason scores form 2 to 6 or no cancer (adjusted odds ratio [OR], 1.04 ng/mL per year; 95% confidence interval [95% CI], 1.003–1.085 ng/mL per year; P = .035). This finding was not evident in patients who had prostate cancers with Gleason scores between 2 and 6 or for any prostate cancer. PSA level was associated with the detection of any prostate cancer (OR, 1.06 ng/mL; 95% CI, 1.03–1.10 ng/mL; P = .004) and Gleason score ≀6 prostate cancer (OR, 1.06 ng/mL; 95% CI, 1.02–1.10 ng/mL; P = .0027); however, in the presence of PSA velocity, PSA no longer remained independently predictive for high‐grade prostate cancer (OR, 1.01 ng/mL; 95% CI, 0.98–1.04 ng/mL; P = .45) after adjusting for established predictors.

CONCLUSIONS.

PSA velocity enhanced the detection of high‐grade cancer in men who had PSA levels >4 ng/mL. These findings, in conjunction with life expectancy, may be used when deciding which men should not be recommended for prostate biopsy despite a PSA level >4 ng/mL. Cancer 2007. Β© 2007 American Cancer Society.


πŸ“œ SIMILAR VOLUMES


Staging for prostate cancer : Time to in
✍ Mack Roach III; Vivian Weinberg; Howard Sandler; Ian Thompson πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 174 KB

## Abstract ## BACKGROUND. The American Joint Committee on Cancer (AJCC) staging system for prostate cancer is based primarily based on clinical tumor (T) classification. In this article, the authors summarize arguments for incorporating additional pretreatment parameters and creating a new stagin

A prospective study of the serum prostat
✍ Jackson E. Fowler Jr.; Steven A. Bigler πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 84 KB πŸ‘ 2 views

## BACKGROUND. The stage specific survival rates of black American men with prostate carcinoma are less favorable than those of white American men. The authors conducted a prospective study of the serum prostate specific antigen (PSA) concentrations and Gleason histologic scores of black and white

Prostate specific antigen outcome based
✍ Anthony V. D'Amico; Richard Whittington; S. Bruce Malkowicz; Delray Schultz; Joh πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 93 KB πŸ‘ 2 views

## BACKGROUND. Early (Υ… 2 years) prostate specific antigen (PSA) failure after radical prostatectomy (RP) has been shown to predict for distant failure. After excluding patients with the pathologic predictors of early PSA failure, an analysis of PSA failure free (bNED) survival was performed to ide

The role of digital rectal examination,
✍ Fred Lee; Peter J. Littrup πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 389 KB

In a study population, can digital rectal examination (DRE), transrectal ultrasound (TRUS), and prostate specific antigen (PSA) (monoclonal) effectively detect the majority of clinically relevant cancer? If this is possible, the remaining patients could then be considered for chemopreventive protoco

Efficacy of androgen deprivation therapy
✍ Robert W. Ross; Wanling Xie; Meredith M. Regan; Mark Pomerantz; Mari Nakabayashi πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 193 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone‐sensitive prostate cancer (HSPC) either with (M+) or without (Mβˆ’) metastases. ## METHODS A cohort of prostate cancer patients was ident